Tag Archives: NICE
By Guest Blogger | Published: January 27, 2014
NICE and Value Based Assessment: An Update By Leela Barham VBA is the new VBP The initial proposals for Value Based Pricing (VBP) have evolved into something very different. Now there is focus on Value Based Assessment (VBA), which is really focusing on adding just two factors to the usual methods of assessing new medicines: […]
By Guest Blogger | Published: January 15, 2014
By Leela Barham. The headlines have moved on for the English Cancer Drugs Fund (CDF). Replacing the positive press releases such as “thousands of patients to benefit” in 2013 are headlines shouting out that “thousands face being denied life-extending medication”. In other words, a return to the same concerns that prompted the creation of the […]
By Guest Blogger | Published: December 10, 2013
By Leela Barham. Collaboration seems to be ‘in’ thing and it’s set to continue in Europe with the European Medicines Agency (EMA) and EUnetHTA agreeing a three-year joint work plan.
By Guest Blogger | Published: December 2, 2013
By Leela Barham. The European Commission mandated that all member states have a plan for rare diseases back in June 2009. With the EC deadline just weeks away, the UK has now finalized its own. But for those who were hoping it would have a clear focus on access to medicines, there’s little to be […]
By Guest Blogger | Published: November 6, 2013
By Leela Barham. Long awaited details have been announced in the Heads of Agreement for the latest Pharmaceutical Price Regulation Scheme (PPRS). It’s worth a read in full (and you can find it here) but some highlights are set out here.